Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay

Journal of Immunological Methods

Volumn 287, Issue 1-2, 2004, Pages 49-65

  Opalka, David ^a   Pessi, Antonello ^b   Bianchi, Elisabetta ^b   Ciliberto, Gennaro ^b   Schleif, William ^a   McElhaugh, Michael ^a   Danzeisen, Renee ^a   Geleziunas, Romas ^a   Miller, Michael ^a   Eckert, Debra M ^a,c   Bramhill, David ^a   Joyce, Joseph ^a   Cook, James ^a   Magilton, William ^a   Shiver, John ^a   Emini, Emilio ^a,d   Esser, Mark T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b IRBM   (Italy)

^c UNIVERSITY OF UTAH   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

Author keywords

Epitope mapping; Human immunodeficiency virus; Luminex; Multiplexed; Neutralizing antibody

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN GP 41; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FUSION; CORRELATION ANALYSIS; EPITOPE MAPPING; FLUORESCENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

AMINO ACID SEQUENCE; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PROTEIN CONFORMATION; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 11144358557     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2004.01.016     Document Type: Article

References (35)

1. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6:2000;200.
2. Barbato G., Bianchi E., Ingallinella P., Hurni W.M., Miller M., Ciliberto G., Cortese R., Bazzo R., Shiver J., Pessi A. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330:2003;1101.
3. Barin F., McLane M.F., Allan J.S., Lee T.H., Groopman J.E., Essex M. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science. 228:1985;1094.
4. Bianchi E., Ingallinella P., Eckert D.M., Cole J.L., Miller M.D., Bazzo R., Barbato G., Pessi A. Conformationally constrained epitope mimics of the HIV gp41 envelope protein. Benedetti E., Pedone C. Peptides 2002. Proc. 27th Eur. Peptide Symposium. 2003;682 Edizioni Ziino, Naples.
5. Biron Z., Khare S., Samson A.O., Hayek Y., Naider F., Anglister J. A monomeric 3(10)-helix is formed in water by a 13-residue peptide representing the neutralizing determinant of HIV-1 on gp41. Biochemistry. 41:2002;12687.
6. Chan D.C., Fass D., Berger J.M., Kim P.S. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 89:1997;263.
7. Chang D.K., Cheng S.F., Trivedi V.D. Biophysical characterization of the structure of the amino-terminal region of gp41 of HIV-1. Implications on viral fusion mechanism. J. Biol. Chem. 274:1999;5299.
8. Eckert D.M., Kim P.S. Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11187.
9. Eckert D.M., Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Ann. Rev. Biochem. 70:2001;777.
10. Eckert D.M., Malashkevich V.N., Hong L.H., Carr P.A., Kim P.S. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket. Cell. 99:1999;103.
11. Finnegan C.M., Berg W., Lewis G.K., DeVico A.L. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J. Virol. 76:2002;12123.
12. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., Achtman M., Densen P., Frasch C.E., Kayhty H.et al. Multicenter comparison of Neisseria meningitides serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J. Clin. Microbiol. 32:1994;1475.
13. Gnann J.W. Jr., Schwimmbeck P.L., Nelson J.A., Truax A.B., Oldstone M.B. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J. Infect. Dis. 156:1987;261.
14. Gottlieb M.S., Schroff R., Schanker H.M., Weisman J.D., Fan P.T., Wolf R.A., Saxon A. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med. 305:1981;1425.
15. Hamilton R.G., Reimer C.B., Rodkey L.S. Quality control of murine monoclonal antibodies using isoelectric focusing affinity immunoblot analysis. Hybridoma. 6:1987;205.
16. Hamilton R.G., Wilson R.W., Spillman T., Roebber M. Monoclonal antibody-based immunoenzymetric assays for quantification of human IgG and its four subclasses. J. Immunoass. 9:1988;275.
17. Joyce J.G., Hurni W.M., Bogusky M.J., Garsky V.M., Liang X., Citron M.P., Danzeisen R.C., Miller M.D., Shiver J.W., Keller P.M. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J. Biol. Chem. 277:2002;45811.
18. Kunert R., Ruker F., Katinger H. Molecular characterization of five neutralizing anti-HIV type 1 antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res. Hum. Retrovir. 14:1998;1115.
19. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 393:1998;648.
20. Mascola J.R., Nabel G.J. Vaccines for the prevention of HIV-1 disease. Curr. Opin. Immunol. 13:2001;489.
21. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6:2000;207.
22. McGaughey G.B., Citron M., Danzeisen R.C., Freidinger R.M., Garsky V.M., Hurni W.M., Joyce J.G., Liang X., Miller M., Shiver J., Bogusky M.J. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry. 42:2003;3214.
23. Opalka D., Lachman C.E., MacMullen S.A., Jansen K.U., Smith J.F., Chirmule N., Esser M.T. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin. Diagn. Lab. Immunol. 10:2003;108.
24. Pai E.F., Klein M.H., Chong P., Pedyczak A. Fab-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5. World Intellectual Property Organization. vol. WO-00:2000;1 University of Toronto, Canada.
25. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schulke N., Katinger H., Moore J.P., Tomer K.B. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. 75:2001;10906.
26. Peisajovich S.G., Epand R.F., Pritsker M., Shai Y., Epand R.M. The polar region consecutive to the HIV fusion peptide participates in membrane fusion. Biochemistry. 39:2000;1826.
27. Plikaytis B.D., Goldblatt D., Frasch C.E., Blondeau C., Bybel M.J., Giebink G.S., Jonsdottir I., Kayhty H., Konradsen H.B., Madore D.V., Nahm M.H., Schulman C.A., Holder P.F., Lezhava T., Elie C.M., Carlone G.M. An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study. J. Clin. Microbiol. 38:2000;2043.
28. Robertson G.A., Kostek B.M., Schleif W.A., Lewis J.A., Emini E.A. A microtiter cell-culture assay for the determination of anti-human immunodeficiency virus neutralizing antibody activity. J. Virol. Methods. 20:1988;195.
29. Root M.J., Kay M.S., Kim P.S. Protein design of an HIV-1 entry inhibitor. Science. 291:2001;884.
30. Salzwedel K., West J.T., Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73:1999;2469.
31. Suzuki K., Hiroaki H., Kohda D., Tanaka T. An isoleucine zipper peptide forms a native-like triple stranded coiled coil in solution. Protein Eng. 11:1998;1051.
32. Vignali D.A. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods. 243:2000;243.
33. Weissenhorn W., Dessen A., Harrison S.C., Skehel J.J., Wiley D.C. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 387:1997;426.
34. Xu J.Y., Gorny M.K., Palker T., Karwowska S., Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J. Virol. 65:1991;4832.
35. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:2001;10892.